About Mithradote Bio
Mithradote Bio is a company based in San Diego (United States) founded in 2023 by Sophia Lee. Mithradote Bio has raised $1 million across 1 funding round from investors including Taho Pharma and Vickers Venture Partners. Mithradote Bio offers products and services including M-101. Mithradote Bio operates in a competitive market with competitors including IgGenix, Tempero Bio, Globin Solutions, Sobrera and metaLead Therapeutics, among others.
- Headquarter San Diego, United States
- Founders Sophia Lee
- SectorsHealthcare
- Website mithradote.com
- Legal Name Mithradote Bio, Inc.
- Total Equity Funding$1 M (USD)
in 1 rounds
- Latest Funding Round$1 M (USD), Seed
Oct 2024
- InvestorsTaho Pharma
& 1 more
Products & Services of Mithradote Bio
Mithradote Bio offers a comprehensive portfolio of products and services, including M-101.
Sublingual pan-antidote to reverse effects of benzodiazepines in drink spiking.
Funding Insights of Mithradote Bio
Mithradote Bio has successfully raised a total of $1M through 1 strategic funding round. The most recent funding activity was a Seed round of $1 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.0M
- Total Rounds 1
- Last Round Seed — $1.0M
- First Round $1.0M
(Oct 2024)
- Investors Count 2
All 1 funding rounds of Mithradote Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2024 | $1.0M | Seed | – | Taho Pharma , Vickers Venture Partners | – |
2 investors in total: 2 institutional.
Investors in Mithradote Bio
Mithradote Bio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Taho Pharma and Vickers Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth-stage venture capital is invested in Singapore and China. | – | vickersventure.com | Singapore, Singapore | |
Company developing CNS and oncology drugs through their proprietary transepithelial drug delivery systems | 2010 | tahopharma.com | Taipei, Taiwan |
Investor details for Mithradote Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mithradote Bio
1 people are tracked at Mithradote Bio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Sophia Lee | Founder & CEO | Leadership |
Complete people profiles for Mithradote Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Mithradote Bio
2 dated milestones of Mithradote Bio across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Mithradote Bio is founded.
- Funding First funding round of $1.0M.
Competitors of Mithradote Bio
Mithradote Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as IgGenix, Tempero Bio, Globin Solutions, Sobrera and metaLead Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| iggenix.com | 2019 | San Francisco, United States | $75.0M | – | Therapeutic solutions for food allergies are developed via antibody platforms. | |
| temperobio.com | 2020 | Oakland, United States | $70.0M | – | Therapeutics for substance use disorders, including opioid-related conditions, are developed. | |
| globinsolutions.com | 2017 | Pittsburgh, United States | $5.0M | – | Antidotal therapies for human poisonings are developed using neuroglobin technology. | |
| sobrera.com | 2019 | Gothenburg, Sweden | – | – | Drugs for alcohol use disorders are developed by Sobrera. | |
| metaleadtherapeutics.tcc.mode | 2022 | Zurich, Switzerland | $170,018 | – | Next-generation medications against metal poisoning are developed. | |
| kaivallabs.com | 2019 | Palm Bay, United States | – | – | Develops innovative technologies for nicotine addiction treatment. | |
| alarpharm.com | 2016 | Taichung, Taiwan | – | – | Drugs for opioid use disorder and depressive disorder are developed. | |
| ovax.com | 2023 | Houston, United States | – | – | Develops technology to predict, prevent, and protect against fentanyl overdoses. | |
| aphiotx.com | 2021 | Calgary, Canada | – | – | Therapeutics targeting pannexin-1 for opioid use disorder are developed. |
Detailed competitors of Mithradote Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Mithradote Bio
10 companies that operate in the same segment as Mithradote Bio (Toxicology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutic solutions for food allergies are developed via antibody platforms. | 2019 | San Francisco, California, United States | USD 75 M | – | – | |
Therapeutics for substance use disorders, including opioid-related conditions, are developed. | 2020 | Oakland, California, United States | USD 70 M | – | – | |
Drug delivery solutions via single-walled carbon nanotubes are offered. | 2008 | Houston, Texas, United States | USD 2.5 M | USD 5.07 M | 9 | |
Non-invasive drug testing technology is developed using fingerprints. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 25.71 M | – | – | |
Provides toxicology, chemistry, and consultancy services for agrochemical industries. | 2020 | Vapi, Gujarat, India | – | – | – | |
Instruments for rapid human DNA identification are developed. | 2006 | Pleasanton, California, United States | USD 92.06 M | USD 22.5 B | 78 | |
Oral therapies for snake bite treatment are developed. | 2015 | Corte Madera, California, United States | USD 16.48 M | – | – | |
Quantitative urine drug testing is provided for patient monitoring. | 2011 | San Diego, California, United States | – | – | 358 | |
Point-of-care platforms for heavy metal toxicity diagnostics are developed. | 1968 | Billerica, Massachusetts, United States | USD 34 M | – | – | |
Real-time trace gas analysis solutions are delivered using SIFT-MS technology. | 2002 | Christchurch, New Zealand | USD 11.9 M | USD 23.52 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Mithradote Bio
Mithradote Bio was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Mithradote Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Sophia Lee is the current CEO of Mithradote Bio. They have also founded this company.
Mithradote Bio is a funded company, having raised a total of $1M across 1 funding round to date. The company's 1st funding round was a Seed of $1M, raised on Oct 2024.
Mithradote Bio was founded in 2023 and is based in San Diego, United States. Operations focus on the biotechnology sector, where medication is developed to counter drug-facilitated sexual assault. A lead product, M-101, is offered as a sublingual pan-antidote targeting benzodiazepines, Z drugs, and other GABA agonists. The company addresses preventive healthcare needs through targeted pharmaceutical solutions.
Mithradote Bio's top competitors include IgGenix, Tempero Bio and Globin Solutions.
Mithradote Bio offers M-101.
Mithradote Bio has 2 investors. Key investors include Taho Pharma, and Vickers Venture Partners.
Mithradote Bio operates through Mithradote Bio, Inc..